Snapshot from Aug 03, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Park Ha Biological Securities Class Action
Regulatory class action

Park Ha Biological Securities Class Action

Analysis based on 6 articles · First reported Aug 01, 2026 · Last updated Aug 02, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit could negatively affect Park Ha Biological Technology Company's stock price and investor confidence, as it alleges securities fraud and stock manipulation. The lawsuit may also increase regulatory scrutiny on the company and potentially lead to financial penalties or settlements.

Biotechnology Securities Litigation
Event Summary

Rosen Law Firm, a global investor rights law firm, announced a class action lawsuit on behalf of purchasers of securities of Park Ha Biological Technology Company Co., Ltd. (Nasdaq: PHH, BYAH) between December 27, 2024 and July 8, 2025. The lawsuit alleges that Park Ha made materially false and misleading statements and failed to disclose material adverse facts about its business, operations, and the true nature of its securities trading activity. Specifically, the defendants failed to disclose that Park Ha was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; that its public statements and risk disclosures omitted mention of false rumors and artificial trading activity driving the stock price; and that its IPO was intentionally structured with an extremely low public float to enable the manipulation scheme. Investors who purchased Park Ha securities during the Class Period may be entitled to compensation. The lead plaintiff deadline is September 28, 2026.

Key Actions
100 Rosen Law Firm filed class action Park Ha Biological Technology Company
Entities Involved
stock
Park Ha Biological Technology Company
Park Ha Biological Technology Company is the defendant in the class action lawsuit, accused of securities fraud and stock manipulation. The lawsuit could result in significant financial liability and reputational damage.
Importance 100.0 Sentiment -70.0
priv
Rosen Law Firm
Rosen Law Firm is the plaintiff's counsel leading the class action lawsuit. The firm stands to gain from potential settlements and reinforces its reputation in securities litigation.
Importance 80.0 Sentiment 20.0
per
Lawrence Rosen
Lawrence Rosen is a founding partner of Rosen Law Firm and is involved in the case as counsel. His involvement is part of the firm's standard practice.
Importance 30.0 Sentiment 10.0
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm and is listed as a contact for the class action. His role is to assist investors in joining the lawsuit.
Importance 30.0 Sentiment 10.0
exch
Nasdaq
Nasdaq is the exchange where Park Ha Biological Technology Company is listed. The lawsuit may affect the stock's trading and could lead to delisting if the company faces severe consequences.
Importance 20.0 Sentiment -10.0
Relationships
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Nasdaq
Lawrence Rosen managing partner ↔ Philip Kim Lawrence Rosen is the founder and managing partner of Rosen Law Firm, where Philip Kim is a partner, and they actively c
Lawrence Rosen related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.